pf-08634404

Small Cell Lung Cancer

PfizerPhase 2/3Active

CCC

54/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 49/ 100
Competitive Position: 65/ 100

Competitive context

290 Active assets in the Small Cell Lung Cancer cohort.

Asset / Sponsor	Phase	Rating
Benmelstobart Yayi He	Phase 4	A
vx-970 National Cancer Institute (NCI)	Phase 2	BBB
Adebelimab Suzhou Suncadia Biopharmaceuticals Co., Ltd.	Phase 3	BBB
Veliparib Central European Society for Anticancer Drug Research	Phase 2	BB
Hycamtin AbbVie	Phase 4	BB

View all 50 →

Same molecule, other indications

pf-08634404 is also rated in:

non-small cell lung carcinomaDormant

BB

Indicative ·

66 / 100

neoplasmDormant

B

Indicative ·

60 / 100

intestinal neoplasmDormant

B

Indicative ·

60 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.